Bruce Cree

Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms 5:12
Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms
Bruce Cree • 13 Jun 2022
Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD cases 1:48
Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD cases
Bruce Cree • 13 Jun 2022
S1P receptor modulators in the treatment of MS 5:43
S1P receptor modulators in the treatment of MS
Bruce Cree • 13 Jun 2022
Key considerations for clinicians treating NMOSD 2:27
Key considerations for clinicians treating NMOSD
Bruce Cree • 13 Jun 2022
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS 4:34
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS
Bruce Cree • 21 Oct 2021
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS 3:57
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS
Bruce Cree • 21 Oct 2021
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD 2:44
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD
Bruce Cree • 21 Oct 2021
Recent evidence for subclinical disease activity in NMOSD 6:38
Recent evidence for subclinical disease activity in NMOSD
Bruce Cree • 21 Oct 2021
The content of VJNeurology is intended for healthcare professionals